Anticorps Polyclonal de lapin anti-VEGFR3/FLT4

VEGFR3/FLT4 Polyclonal Antibody for WB, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, souris

Applications

WB, IHC, IF, ELISA

Conjugaison

Non conjugué

Publications(17)

N° de cat : 20712-1-AP

Synonymes

FLT4, Fms like tyrosine kinase 4, FLT41, FLT-4, FLT 4



Applications testées

Résultats positifs en WBtissu splénique de souris, cellules HeLa, cellules PC-3, tissu cardiaque de souris

Dilution recommandée

ApplicationDilution
Western Blot (WB)WB : 1:200-1:1000
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, check data in validation data gallery

Informations sur le produit

20712-1-AP cible VEGFR3/FLT4 dans les applications de WB, IHC, IF, ELISA et montre une réactivité avec des échantillons Humain, souris

Réactivité Humain, souris
Réactivité citéeHumain, souris
Hôte / Isotype Lapin / IgG
Clonalité Polyclonal
Type Anticorps
Immunogène Peptide
Nom complet fms-related tyrosine kinase 4
Masse moléculaire calculée 153 kDa
Poids moléculaire observé 125 kDa
Numéro d’acquisition GenBankNM_002020
Symbole du gène FLT4
Identification du gène (NCBI) 2324
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Purification par affinité contre l'antigène
Tampon de stockage PBS with 0.02% sodium azide and 50% glycerol
Conditions de stockageStocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA.

Informations générales

FLT4, also named VEGFR-3, belongs to the protein kinase superfamily, Tyr protein kinase family, and CSF-1/PDGF receptor subfamily. It is a receptor for VEGFC. FLT4 has a tyrosine-protein kinase activity. Defects in FLT4 cause lymphedema hereditary type 1 (LYH1A). Defects in FLT4 are found in juvenile hemangioma. VEGFR-3 is a highly glycosylated protein and migrates as bands with different molecular weights: an ~175 kDa precursor, an ~195 kDa mature form, an ~140 kDa non-glycosylated backbone, and a form that appears to be partially cleaved proteolytically in the extracellular domain to produce an ~125 kDa band(PMID: 15389531).

Protocole

Product Specific Protocols
WB protocol for VEGFR3/FLT4 antibody 20712-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
humanIF

Mol Cancer

m6A methylation reader IGF2BP2 activates endothelial cells to promote angiogenesis and metastasis of lung adenocarcinoma

Authors - Han Fang
humanWB

Int J Biol Sci

PROTAC-Surufatinib Suppresses Pancreatic Neuroendocrine Neoplasms Progression by Inducing Ferroptosis through Inhibiting WNT/β-catenin Pathway Mediated by HMOX1

Authors - Bingyan Xue
humanIHC

Front Oncol

The Specifically Androgen-Regulated Gene (SARG) Promotes Papillary Thyroid Carcinoma (PTC) Lymphatic Metastasis Through Vascular Endothelial Growth Factor C (VEGF-C) and VEGF Receptor 3 (VEGFR-3) Axis.

Authors - Shuai-Jun Xu
DeerWB

Stem Cell Res Ther

Deer thymosin beta 10 functions as a novel factor for angiogenesis and chondrogenesis during antler growth and regeneration.

Authors - Wei Zhang
humanWB

Pharmaceuticals (Basel)

Use of Early Donated COVID-19 Convalescent Plasma Is Optimal to Preserve the Integrity of Lymphatic Endothelial Cells.

Authors - Nada Amri
humanWB

Mol Cell Endocrinol

Long noncoding RNA GAS5 accelerates diabetic wound healing and promotes lymphangiogenesis via miR-217/Prox1 axis.

Authors - Zhi-You He

Avis

The reviews below have been submitted by verified Proteintech customers who received an incentive for providing their feedback.


FH

Shinford (Verified Customer) (12-15-2023)

We used the concentration of 1:500 to get a very strong band. It is a big volume set.

  • Applications: Western Blot
  • Primary Antibody Dilution: 1:500
  • Cell Tissue Type: Lung cancer cell lines, lung cancer tissues
VEGFR3/FLT4 Antibody Western Blot validation (1:500 dilution) in Lung cancer cell lines, lung cancer tissues (Cat no:20712-1-AP)
{{ptg:RelatedPrimaryAntibodies}}